Breaking
Thursday, June 18, 2026

Clinical Trials Analysis

🌏 NMPA

Expert commentary and market intelligence for pharma strategy teams

Showing 1–12 of 21 articles

High impact AnalysisJun 9, 2026

Drug Discovery Technology Market Size Tops USD 80.27 Billion by 2035

5 min

Dr. Yuki Tanaka
High impact AnalysisJun 9, 2026

Clinical Trials Outsourcing Market Size: 2026-2034 Growth Outlook

5 min

Dr. Yuki Tanaka
High impact AnalysisJun 8, 2026

Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context

atopic dermatitis · 5 min

Dr. Yuki Tanaka
Critical impact AnalysisJun 6, 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Data at ADA 2026

GLP-1 · 5 min

Dr. Yuki Tanaka
High impact AnalysisJun 6, 2026

ASCO26: Revolution's Daraxonrasib Phase III Data Reshapes Pancreatic Cancer Odds

oncology · 7 min

Dr. Yuki Tanaka
High impact AnalysisJun 5, 2026

Poly Medicure appoints Indranil Mukherjee as CEO, APAC & India: Strategic implications for pharma BD teams

4 min

Dr. Yuki Tanaka
High impact AnalysisJun 5, 2026

Cell Therapy Packaging Market Size & Share Report, 2033: Key Trends and Forecasts

cell therapy · 4 min

Dr. Yuki Tanaka
High impact AnalysisJun 5, 2026

Orion Pharma's ODM-212 Shows Favorable Safety in Phase 1/2 TEADES Trial for Advanced Solid Tumours

advanced solid tumours · 4 min

Dr. Yuki Tanaka
High impact AnalysisJun 5, 2026

The Pharma Choke Point: A Strategic Risk for U.S. Pharmaceutical Supply Chains

5 min

Dr. Yuki Tanaka
High impact AnalysisJun 5, 2026

Ecosystem Over Geography: Life Sciences Location Strategy in APAC

EMA · 5 min

Dr. Yuki Tanaka
High impact AnalysisJun 4, 2026

Helus Pharma to Participate in the Jefferies Global Healthcare Conference: Strategic Implications for Analysts and BD Teams

4 min

Dr. Yuki Tanaka
High impact AnalysisJun 3, 2026

Acclinate and HCN Global Forge Strategic Partnership to Enhance Clinical Research Diversity

6 min

Dr. Yuki Tanaka